Abstract
7540 Background: Adjuvant chemotherapy for NSCLC has reached a plateau. The use of the tyrosine kinase inhibitor (TKI), E, was explored in the adjuvant setting given success in advanced setting.We ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have